Iguana Healthcare Management LLC maintained its position in shares of Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,000 shares of the medical research company’s stock at the close of the 1st quarter. Amgen makes up about 4.1% of Iguana Healthcare Management LLC’s investment portfolio, making the stock its 5th biggest holding. Iguana Healthcare Management LLC’s holdings in Amgen were worth $8,204,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. Berkshire Asset Management LLC PA boosted its holdings in shares of Amgen by 4.0% in the 1st quarter. Berkshire Asset Management LLC PA now owns 115,837 shares of the medical research company’s stock valued at $19,005,000 after buying an additional 4,409 shares during the last quarter. Cullinan Associates Inc. lifted its holdings in Amgen by 19.0% during the 1st quarter. Cullinan Associates Inc. now owns 81,189 shares of the medical research company’s stock valued at $13,321,000 after purchasing an additional 12,960 shares during the last quarter. Oliver Luxxe Assets LLC lifted its holdings in Amgen by 23.9% during the 1st quarter. Oliver Luxxe Assets LLC now owns 4,704 shares of the medical research company’s stock valued at $772,000 after purchasing an additional 908 shares during the last quarter. Carderock Capital Management Inc. lifted its holdings in Amgen by 3.2% during the 1st quarter. Carderock Capital Management Inc. now owns 27,629 shares of the medical research company’s stock valued at $4,533,000 after purchasing an additional 848 shares during the last quarter. Finally, Howe & Rusling Inc. lifted its holdings in Amgen by 1.1% during the 1st quarter. Howe & Rusling Inc. now owns 2,956 shares of the medical research company’s stock valued at $485,000 after purchasing an additional 31 shares during the last quarter. 78.13% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Iguana Healthcare Management LLC Has $8,204,000 Holdings in Amgen Inc. (AMGN)” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://sportsperspectives.com/2017/09/10/iguana-healthcare-management-llc-has-8204000-holdings-in-amgen-inc-amgn.html.
Amgen Inc. (NASDAQ AMGN) traded down 0.04% during mid-day trading on Friday, reaching $180.64. The company had a trading volume of 1,993,947 shares. The stock has a 50 day moving average price of $173.77 and a 200-day moving average price of $168.79. The stock has a market capitalization of $131.81 billion, a P/E ratio of 16.45 and a beta of 1.35. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.84 EPS. Equities analysts anticipate that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were paid a $1.15 dividend. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.55%. Amgen’s dividend payout ratio is currently 41.93%.
Several equities research analysts have issued reports on AMGN shares. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $189.00 price target on shares of Amgen in a report on Friday, June 30th. BidaskClub raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Jefferies Group LLC reaffirmed a “hold” rating and set a $180.00 price target on shares of Amgen in a report on Monday, May 22nd. Credit Suisse Group set a $177.00 price target on Amgen and gave the company a “hold” rating in a report on Friday, July 14th. Finally, Morgan Stanley raised their price target on Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, June 13th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $186.04.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.